Clinical trials recruiting for Ras (KRAS or NRAS) Gene Mutation
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Leflunomide | 1 |
| NST-628 | 1 |
| The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 1 |
| Colorado | 1 |
| Connecticut | 1 |
| Florida | 1 |
| New York | 1 |
| Pennsylvania | 1 |
| Tennessee | 1 |
| Texas | 1 |
| Utah | 1 |
| Virginia | 1 |
Top cities
Self-screener
Recruiting trials
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
- Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Related conditions
Trials recruiting for Ras (KRAS or NRAS) Gene Mutation often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Ras (KRAS or NRAS) Gene Mutation trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.